Parainfluenza virus type 3 infectious disease
MONDO:0042974Parainfluenza virus type 3 is one of a group of common viruses known as human parainfluenza viruses (HPIV) that cause a variety of respiratory illnesses. Symptoms usually develop between 2 and 7 days from the time of exposure and typically resolve in 7-10 days. Symptoms may include fever, runny nose, and cough. HPIV-3 can also cause bronchiolitis, bronchitis, and pneumonia. Infants and young children are particularly susceptible to HPIV-3 infections, though older adults and those with a weakened immune system are also at risk for complications. HPIVs are usually spread from an infected person to others through coughing, sneezing, and/or touching. There is currently no vaccine to protect against parainfluenza virus infections. Most HPIV infections resolve on their own and do not require special treatment, though medical intervention may be necessary for severe breathing problems. Most adults have antibodies against parainfluenza but can get repeat infections.
Also known as: human respirovirus 3 caused disease or disorder, human respirovirus 3 disease or disorder, human respirovirus 3 infectious disease, infection due to human parainfluenza virus 3, PIV3, human parainfluenza virus type 3, infection caused by human parainfluenza virus 3, infection caused by parainfluenza virus 3
7 clinical trials for this condition and its sub-types, 4 tagged with Parainfluenza virus type 3 infectious disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Parainfluenza virus type 3 infectious disease
-
Triple threat vaccine aims to shield seniors from three winter viruses
Vaccine OngoingThis early-stage study tests a new vaccine called VXB-251 in 240 healthy adults aged 60-83. The vaccine is designed to protect against three viruses that can cause serious lung infections: RSV, hMPV, and PIV3. Researchers will check if the vaccine is safe and how well it triggers…
Phase 1 • Sponsor: Sanofi • Aim: Vaccine
Last updated Jun 27, 2026 12:35 UTC
-
Scientists compare immune responses to viral and bacterial infections in ICU patients
Knowledge-focused OngoingThis study looks at how the immune system of patients in the intensive care unit (ICU) responds to severe infections caused by viruses or bacteria. Researchers will take extra blood samples from 38 adults to analyze immature granulocytes, a type of immune cell. The goal is to see…
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC